IPP Bureau
Orchid Pharma's Exblifeb granted EMA approval
By IPP Bureau - February 01, 2024
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr
By IPP Bureau - February 01, 2024
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study
By IPP Bureau - January 31, 2024
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
By IPP Bureau - January 31, 2024
Submission to be reviewed under FDA real-time oncology review and Project Orbis
100 bedded Yoga & Naturopathy Hospital to come up in Dibrugarh
By IPP Bureau - January 30, 2024
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40
By IPP Bureau - January 30, 2024
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Glenmark, Ichnos Sciences form ‘Ichnos Glenmark Innovation’ for new drug discovery in cancer treatment
By IPP Bureau - January 30, 2024
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Eastman, SEG collaborate to launch INVU 10th anniversary collection with Tritan Renew
By IPP Bureau - January 30, 2024
Tritan Renew, which is made with 50% certified recycled content derived from hard-to-recycle waste, performs like virgin-quality material
Covestro’s new medical polycarbonate pushes the boundaries of heat resistance
By IPP Bureau - January 30, 2024
Combines biocompatibility, heat-resistance, transparency and durability
EMA validates Type II variation application for enfortumab vedotin with pembrolizumab for treatment of bladder cancer
By IPP Bureau - January 29, 2024
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Merck’s Keytruda reduced the risk of death by 38% for patients with RCC
By IPP Bureau - January 29, 2024
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Jubilant Pharmova Singapore to sell its entire 25.8% stake in Sofie Biosciences, USA
By IPP Bureau - January 29, 2024
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
Jiangsu Alphamab, 3D Medicines and Glenmark sign license agreement for Envafolimab
By IPP Bureau - January 29, 2024
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Indian Red Cross Society and Cadila to launch training of 50,000 students for CPR and First Aid
By IPP Bureau - January 29, 2024
The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state
